Triggering of Suicidal Erythrocyte Death by Ruxolitinib
Background/Aims: The JAK1/JAK2 tyrosine kinase inhibitor ruxolitinib is widely used for the treatment of myeloproliferative neoplasm-associated myelofibrosis and other malignancies. Most important side effects include anemia. A common cause of anemia is accelerated suicidal death of erythrocytes or...
Tallennettuna:
| Päätekijät: | , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Cell Physiol Biochem Press GmbH & Co KG
2015-09-01
|
| Sarja: | Cellular Physiology and Biochemistry |
| Aiheet: | |
| Linkit: | http://www.karger.com/Article/FullText/430394 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|